OncoCyte - OCX Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings or view top-rated stocks.

4 brokers have issued 12-month price objectives for OncoCyte's stock. Their OCX share price forecasts range from $0.50 to $3.00. On average, they expect the company's share price to reach $1.35 in the next year. This suggests a possible upside of 255.3% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.

OncoCyte's stock was trading at $0.3209 at the start of the year. Since then, OCX shares have increased by 18.4% and is now trading at $0.38.
View the best growth stocks for 2023 here.

OncoCyte saw a decline in short interest in January. As of January 15th, there was short interest totaling 1,410,000 shares, a decline of 16.6% from the December 31st total of 1,690,000 shares. Based on an average trading volume of 414,300 shares, the short-interest ratio is presently 3.4 days.
View OncoCyte's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our OCX earnings forecast.

OncoCyte Co. (NASDAQ:OCX) issued its earnings results on Thursday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $1.02 million for the quarter, compared to the consensus estimate of $1.50 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 54.99%.

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.92%), Penbrook Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends.

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCX stock can currently be purchased for approximately $0.38.

OncoCyte (NASDAQ:OCX) has a market capitalization of $45.08 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.